Alexander L. Weis
Chief Executive Officer at ONCOVISTA INNOVATIVE THERAPIES, INC.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
William J. Brock | M | 74 |
OncoVista-Sub
| 17 years |
Alexander Ruckdaeschel | M | 52 |
OncoVista-Sub
| 19 years |
Winfried Albert | M | - |
Alere Diagnostics GmbH
Alere Diagnostics GmbH Medical SpecialtiesHealth Technology Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany. | 22 years |
Siegfried Hauch | M | - |
Alere Diagnostics GmbH
Alere Diagnostics GmbH Medical SpecialtiesHealth Technology Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany. | - |
Axel Bruemmer | M | - |
Alere Diagnostics GmbH
Alere Diagnostics GmbH Medical SpecialtiesHealth Technology Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany. | - |
Timm Diestel | M | - |
Alere Diagnostics GmbH
Alere Diagnostics GmbH Medical SpecialtiesHealth Technology Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany. | - |
Inga Wieling | M | - |
Alere Diagnostics GmbH
Alere Diagnostics GmbH Medical SpecialtiesHealth Technology Alere Diagnostics GmbH develops diagnostics to detect circulating tumor cells in tumor patients. The company's tumor diagnostics are kits consisting of reagents for immunomagnetic selection, mRNA isolation and multiplex RT-PCR and can be performed on standard technology platforms. The products have analytical sensitivity (2 cells in 5 ml blood) and specificity (greater 90%) achieved through the combination of multi-marker tumor cell enrichment and multiplex gene expression profiling for treatment of cancer. The company was founded in 1999 and is headquartered in Langenhagen, Germany. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
J. Edwards | M | 57 | - | |
Corey Levenson | M | 69 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 10 years |
Richard L. Love | M | 81 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | 10 years |
Michael F. Moloney | M | 65 | 3 years | |
Paul Anthony Mieyal | M | 55 | 1 years | |
James Carman Wemett | M | 75 | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 8 | 61.54% |
Germany | 5 | 38.46% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alexander L. Weis
- Personal Network